[医药制造业] [2025-03-22]
Bispecific antibodies for cancer are artificial proteins that simultaneously target two or more tumor antigens on the same or separate cells to interrupt cancer progression. They can simultaneously block two different pathways that employ unique pathogenesis.
[医药制造业] [2025-03-22]
Biosimilars are highly similar versions of biological drugs derived from living microorganisms found in plant or animal cells. They are nearly identical in structure and function to an original biological drug.
[医药制造业] [2025-03-22]
Biopharmaceutical analytical testing services include analytical laboratory testing that is focused on the selection of package and delivery systems to advance early-stage drug products through the development process.
[医药制造业] [2025-03-22]
Various CNS stimulants, such as lisdexamfetamine, methamphetamine, amphetamine, and armodafinil, are used to treat CNS disorders and their symptoms. These stimulants act by increasing the dopamine level in the brain, which increases blood pressure and heart rate.
[医药制造业] [2025-03-22]
Chronic disease management refers to the use of tools and software to manage the symptoms of long-term illnesses and improve monitoring chronic conditions, ensuring the well-being and safety of individuals.
[医药制造业] [2025-03-20]
1月31日,艾伯维公布了2024年业绩,全年总营收563.34亿美元,同比增长3.7%。研发投入为127.91亿美元,同比增长66.7%。艾伯维将2027年Skyriz和Rinvoq合并销售预期上调至超过270亿美元,其中Skyriz销售额预计超过170亿美元,Rinvoq销售额预计超过100亿美元。
[医药制造业] [2025-03-20]
遮蔽技术(遮蔽肽/空间位阻遮蔽等)是近年免疫疗法中的热点领域,其是一种应对靶向性和非靶向性细胞毒性的解决策略。从早期临床结果来看,这一技术能够降低抗体类药物的不良反应,不仅能够增加现有药物的治疗窗,减毒增效;更能给未成药靶点带去成药曙光。关键点在于:遮蔽肽可以提升药物给药剂量。
[医药制造业,信息传输、软件和信息技术服务业] [2025-03-20]
脑机接口在医疗领域具有发展潜力:脑机接口(Brain-Computer Interface, BCI)技术是一种通过解读大脑信号来控制外部设备的技术,可以直接从大脑获取信息并将其转换为可操作的指令。在医疗保健领域,BCI 可以显著改善患有严重运动障碍或其他神经系统疾病患者的生活质量,具有极大的发展潜力。
[医药制造业] [2025-03-20]
特殊医学用途配方食品(后称“特医食品”)是为了满足进食受限、消化吸收障碍、代谢紊乱或特定疾病状态人群对营养素或膳食的特殊需要,专门加工配制而成的配方食品。该类产品必须在医生或临床营养师指导下,单独食用或与其他食品配合食用。
[医药制造业] [2025-03-20]
1、核心观点—中药板块行情将启 p 我们预计中药板块将于2025Q2迎来业绩拐点,板块行情或提前于业绩拐点显现而启动。2、核心指标跟踪 p 流感数据趋于平稳,收入增速环比改善 p 中药材价格指数回落,毛利率压力有望缓解 p 基金持仓偏轻,已回落至防疫政策优化前水平 p 板块估值低于2021年以来平均值和中位数 3、投资逻辑—看好品种品牌力强的院外央国企 p 股权激励为业绩稳增长保驾护航 p 高分红提供持续稳定的股东回报